Vidaza price?

How much does Vidaza (azacitidine) cost?
Vidaza’s list price varies by dosage form, but a single 1‑gram vial typically runs in the $7,500‑$8,000 range【1】. A full treatment cycle—usually 7 or 14 days of daily injections—requires several vials, pushing the total cost for a cycle up to $60,000 or more.

Why is Vidaza so expensive?
The cost reflects the drug’s complex manufacturing process, the need for cold‑chain storage, and the fact that azacitidine is a specialty oncology drug with no generic equivalent yet. Pricing also incorporates the value placed on its efficacy in treating myelodysplastic syndromes and certain leukemias.

Can insurers or patient‑assistance programs reduce the price?
Many Medicare and commercial plans cover Vidaza under specialty drug benefit structures, often requiring prior authorization and a step‑down to a preferred drug list. Patient‑assistance programs, such as the Vidaza Patient Assistance Program, may provide copay help or full coverage for eligible patients, depending on income and insurance status.

What is the cost per dose or per cycle?
A standard 7‑day course uses 10–11 vials (one vial per day) and can cost roughly $70,000–$80,000 in total. A 14‑day course doubles the vial count, pushing the cycle cost close to $140,000. These figures are based on the average list price per vial.

How does Vidaza’s price compare to other hypomethylating agents?
Competing drugs such as decitabine (Dacogen) and low‑dose cytarabine have similar per‑vial prices, though dosing schedules differ. In terms of total cycle cost, Vidaza is comparable to these agents, with some clinicians citing it as the most expensive among them.

When does the patent protection for Vidaza expire?
Azacitidine’s original patent protection for the drug’s active ingredient expired in 2018, but patents on specific formulations and delivery methods continue to extend exclusivity. The current formulation patents are set to expire in the late 2020s, after which generic competition is expected to reduce prices.

Can biosimilars enter the market before patent expiry?
Because azacitidine is a small‑molecule drug rather than a biologic, true biosimilars do not apply. Generic manufacturers can launch once all exclusivity periods lapse, but they must demonstrate bioequivalence through regulatory studies.

What are the main risks or uncertainties that could affect Vidaza pricing?
- Regulatory changes in specialty drug reimbursement or pricing caps.
- New clinical evidence that could shift practice patterns toward or away from azacitidine.
- Generic competition after patent expiry could lower the price substantially.

Is there a way to estimate total out‑of‑pocket costs?
Patients can use pharmacy benefit managers’ tools and manufacturer copay calculators. The average copay for a single vial is $300–$400 under many insurance plans, but this varies widely with the specific policy and deductible levels.

Sources
1. DrugPatentWatch.com – Vidaza pricing data. https://www.drugpatentwatch.com/drugs/vidaza/price